356 related articles for article (PubMed ID: 25506674)
1. Frequency of cholinergic and caudate nucleus dopaminergic deficits across the predemented cognitive spectrum of Parkinson disease and evidence of interaction effects.
Bohnen NI; Albin RL; Müller ML; Petrou M; Kotagal V; Koeppe RA; Scott PJ; Frey KA
JAMA Neurol; 2015 Feb; 72(2):194-200. PubMed ID: 25506674
[TBL] [Abstract][Full Text] [Related]
2. Diabetes mellitus is independently associated with more severe cognitive impairment in Parkinson disease.
Bohnen NI; Kotagal V; Müller ML; Koeppe RA; Scott PJ; Albin RL; Frey KA; Petrou M
Parkinsonism Relat Disord; 2014 Dec; 20(12):1394-8. PubMed ID: 25454317
[TBL] [Abstract][Full Text] [Related]
3. Striatal and Cortical β-Amyloidopathy and Cognition in Parkinson's Disease.
Shah N; Frey KA; Müller ML; Petrou M; Kotagal V; Koeppe RA; Scott PJ; Albin RL; Bohnen NI
Mov Disord; 2016 Jan; 31(1):111-7. PubMed ID: 26380951
[TBL] [Abstract][Full Text] [Related]
4. Thalamic cholinergic innervation and postural sensory integration function in Parkinson's disease.
Müller ML; Albin RL; Kotagal V; Koeppe RA; Scott PJ; Frey KA; Bohnen NI
Brain; 2013 Nov; 136(Pt 11):3282-9. PubMed ID: 24056537
[TBL] [Abstract][Full Text] [Related]
5. Clinical markers for identifying cholinergic deficits in Parkinson's disease.
Müller ML; Bohnen NI; Kotagal V; Scott PJ; Koeppe RA; Frey KA; Albin RL
Mov Disord; 2015 Feb; 30(2):269-73. PubMed ID: 25393613
[TBL] [Abstract][Full Text] [Related]
6. Gender differences in cholinergic and dopaminergic deficits in Parkinson disease.
Kotagal V; Albin RL; Müller ML; Koeppe RA; Frey KA; Bohnen NI
J Neural Transm (Vienna); 2013 Oct; 120(10):1421-4. PubMed ID: 23532360
[TBL] [Abstract][Full Text] [Related]
7. Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy.
Jokinen P; Brück A; Aalto S; Forsback S; Parkkola R; Rinne JO
Parkinsonism Relat Disord; 2009 Feb; 15(2):88-93. PubMed ID: 18434233
[TBL] [Abstract][Full Text] [Related]
8. Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study.
Rinne JO; Portin R; Ruottinen H; Nurmi E; Bergman J; Haaparanta M; Solin O
Arch Neurol; 2000 Apr; 57(4):470-5. PubMed ID: 10768619
[TBL] [Abstract][Full Text] [Related]
9. Diabetes, Gray Matter Loss, and Cognition in the Setting of Parkinson Disease.
Petrou M; Davatzikos C; Hsieh M; Foerster BR; Albin RL; Kotagal V; Müller ML; Koeppe RA; Herman WH; Frey KA; Bohnen NI
Acad Radiol; 2016 May; 23(5):577-81. PubMed ID: 26874576
[TBL] [Abstract][Full Text] [Related]
10. Mentally stimulating activities associate with better cognitive performance in Parkinson disease.
Bohnen JLB; Müller MLTM; Haugen J; Bohnen NI
J Neural Transm (Vienna); 2017 Oct; 124(10):1205-1212. PubMed ID: 28726034
[TBL] [Abstract][Full Text] [Related]
11. Functional brain imaging of cognitive dysfunction in Parkinson's disease.
Hirano S; Shinotoh H; Eidelberg D
J Neurol Neurosurg Psychiatry; 2012 Oct; 83(10):963-9. PubMed ID: 22807560
[TBL] [Abstract][Full Text] [Related]
12. Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease.
Kotagal V; Albin RL; Müller ML; Koeppe RA; Chervin RD; Frey KA; Bohnen NI
Ann Neurol; 2012 Apr; 71(4):560-8. PubMed ID: 22522445
[TBL] [Abstract][Full Text] [Related]
13. Gait speed in Parkinson disease correlates with cholinergic degeneration.
Bohnen NI; Frey KA; Studenski S; Kotagal V; Koeppe RA; Scott PJ; Albin RL; Müller ML
Neurology; 2013 Oct; 81(18):1611-6. PubMed ID: 24078735
[TBL] [Abstract][Full Text] [Related]
14. Interaction of caudate dopamine depletion and brain metabolic changes with cognitive dysfunction in early Parkinson's disease.
Polito C; Berti V; Ramat S; Vanzi E; De Cristofaro MT; Pellicanò G; Mungai F; Marini P; Formiconi AR; Sorbi S; Pupi A
Neurobiol Aging; 2012 Jan; 33(1):206.e29-39. PubMed ID: 20961661
[TBL] [Abstract][Full Text] [Related]
15. Extra-nigral pathological conditions are common in Parkinson's disease with freezing of gait: an in vivo positron emission tomography study.
Bohnen NI; Frey KA; Studenski S; Kotagal V; Koeppe RA; Constantine GM; Scott PJ; Albin RL; Müller ML
Mov Disord; 2014 Aug; 29(9):1118-24. PubMed ID: 24909584
[TBL] [Abstract][Full Text] [Related]
16. Cortical activity in Parkinson's disease during executive processing depends on striatal involvement.
Monchi O; Petrides M; Mejia-Constain B; Strafella AP
Brain; 2007 Jan; 130(Pt 1):233-44. PubMed ID: 17121746
[TBL] [Abstract][Full Text] [Related]
17. History of falls in Parkinson disease is associated with reduced cholinergic activity.
Bohnen NI; Müller ML; Koeppe RA; Studenski SA; Kilbourn MA; Frey KA; Albin RL
Neurology; 2009 Nov; 73(20):1670-6. PubMed ID: 19917989
[TBL] [Abstract][Full Text] [Related]
18. Subcortical white matter hyperintensities within the cholinergic pathways of Parkinson's disease patients according to cognitive status.
Shin J; Choi S; Lee JE; Lee HS; Sohn YH; Lee PH
J Neurol Neurosurg Psychiatry; 2012 Mar; 83(3):315-21. PubMed ID: 22228726
[TBL] [Abstract][Full Text] [Related]
19. In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson's disease.
Ray NJ; Bradburn S; Murgatroyd C; Toseeb U; Mir P; Kountouriotis GK; Teipel SJ; Grothe MJ
Brain; 2018 Jan; 141(1):165-176. PubMed ID: 29228203
[TBL] [Abstract][Full Text] [Related]
20. Spatiotemporal Progression Patterns of Dopamine Availability and Deep Gray Matter Volume in Parkinson Disease-Related Cognitive Impairment.
Oh Y; Kim JS; Lyoo CH; Park G; Kim H
Neurology; 2024 Jul; 103(2):e209498. PubMed ID: 38885485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
